Qiagen N.V.

Report azionario NYSE:QGEN

Capitalizzazione di mercato: US$8.4b

Qiagen Performance degli utili passati

Criteri Il passato verificati 4/6

Gli utili di Qiagen sono diminuiti a un tasso medio annuo di -13.1%, mentre il settore Life Sciences ha visto gli utili diminuire a un tasso medio annuo di 3.5%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 2.1%. Il ritorno sul capitale proprio di Qiagen è 12.1% e ha margini netti di 19.2%.

Informazioni chiave

-13.14%

Tasso di crescita degli utili

-13.37%

Tasso di crescita dell'EPS

Life Sciences Crescita del settore21.51%
Tasso di crescita dei ricavi-2.11%
Rendimento del capitale proprio12.07%
Margine netto19.16%
Prossimo aggiornamento sugli utili05 Aug 2026

Aggiornamenti sulle prestazioni recenti

Recent updates

Seeking Alpha • Jul 12

Qiagen: New Launches Signal A Turnaround

Summary Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 09

QGEN: Reset Expectations And Product Pipeline Will Shape Medium Term Outlook

Analysts now place Qiagen's fair value at $36, down from $38. This reflects a reset in expectations around QuantiFERON growth and recent price target reductions, which offset more constructive views on the stock's longer term positioning and valuation.
Aggiornamento narrativa • Jun 25

QGEN: Expect Post Pandemic Testing Demand To Support Oncology And Diagnostics Expansion

Analysts have adjusted the fair value estimate for Qiagen slightly higher to $43.96 from $43.82, reflecting a modestly higher discount rate, alongside mixed recent price target moves that highlight both concerns over growth in areas like QuantiFERON and renewed interest in the stock as a potential structural beneficiary of post pandemic demand trends. Analyst Commentary Recent Street research on Qiagen reflects a split view, with some bullish analysts pointing to potential growth opportunities and valuation support, while more cautious analysts focus on execution risks and reduced expectations in key product areas.
Articolo di analisi • Jun 21

Qiagen (QGEN) Stock Could Be 15.7% Undervalued After QIAcuity Expansion

Qiagen (NYSE:QGEN) is in focus after announcing new additions to its QIAcuity digital PCR ecosystem, including expanded gene expression tools, higher multiplexing and upgraded software and automation for high throughput labs. See our latest analysis for Qiagen. The QIAcuity update comes as Qiagen’s share price has shown mixed momentum, with a 1-month share price return of 5.06%, a year-to-date share price return that is down 22.32%, and a 5-year total shareholder return that is down 23.67%...
Aggiornamento narrativa • Jun 06

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostics Expansion Beyond Current Headwinds

Qiagen's updated analyst price target has been reduced by about $9.70. This reflects analysts' lower growth and profitability assumptions after recent cuts across the Street tied to softer QuantiFERON trends and a rebased full year outlook.
Nuova narrativa • May 15

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
Nuova narrativa • Apr 30

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
Aggiornamento narrativa • Apr 29

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.
Aggiornamento narrativa • Apr 10

QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns

Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.
Aggiornamento narrativa • Mar 27

QGEN: Possible Sale Prospects Are Expected To Drive Future Returns

The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.
Aggiornamento narrativa • Mar 12

QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns

The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.
Aggiornamento narrativa • Feb 25

QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside

Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.
Aggiornamento narrativa • Feb 11

QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks

Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.
Aggiornamento narrativa • Jan 28

QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition

Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.
Aggiornamento narrativa • Jan 08

QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions

Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).
Articolo di analisi • Jan 07

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued

Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...
Aggiornamento narrativa • Dec 14

QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead

Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.
Aggiornamento narrativa • Nov 29

QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms

Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.
Aggiornamento narrativa • Nov 15

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.
Articolo di analisi • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
Aggiornamento narrativa • Oct 31

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.
Aggiornamento narrativa • Oct 17

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.
Aggiornamento narrativa • Oct 03

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.
Aggiornamento narrativa • Sep 04

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.
Articolo di analisi • Sep 02

Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality

Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...
Articolo di analisi • Aug 08

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...
Articolo di analisi • Aug 05

Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...
Seeking Alpha • Feb 25

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking Alpha

Ripartizione dei ricavi e delle spese

Come Qiagen guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NYSE:QGEN Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
31 Mar 262,099402588192
31 Dec 252,090425584188
30 Sep 252,071405572189
30 Jun 252,040373569185
31 Mar 252,00394564186
31 Dec 241,97884564193
30 Sep 241,96693569191
30 Jun 241,94073568194
31 Mar 241,939337570195
31 Dec 231,965341579199
30 Sep 231,954332587197
30 Jun 231,978337593198
31 Mar 231,999353599198
31 Dec 222,142423604190
30 Sep 222,226488618178
30 Jun 222,261539616177
31 Mar 222,313563606180
31 Dec 212,252513584190
30 Sep 212,240311604184
30 Jun 212,190480572182
31 Mar 212,065449549162
31 Dec 201,870359525149
30 Sep 201,713191522137
30 Jun 201,61214517142
31 Mar 201,550-31530151
31 Dec 191,526-41530157
30 Sep 191,516-25502164
30 Jun 191,511196492164
31 Mar 191,507188508163
31 Dec 181,502190497162
30 Sep 181,49690476162
30 Jun 181,48278474158
31 Mar 181,45355466157
31 Dec 171,41840478154
30 Sep 171,38789467145
30 Jun 171,36275480143
31 Mar 171,34782480147
31 Dec 161,33880470150
30 Sep 161,320123485157
30 Jun 161,296123471157
31 Mar 161,281126450148
31 Dec 151,281130445147
30 Sep 151,293104475151

Guadagni di qualità: QGEN ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di QGEN (19.2%) QGEN sono più alti rispetto allo scorso anno (4.7%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di QGEN sono diminuiti del 13.1% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di QGEN nell'ultimo anno ( 329.3% ) supera la media quinquennale ( -13.1% all'anno).

Guadagni vs Settore: La crescita degli utili QGEN nell'ultimo anno ( 329.3% ) ha superato la percentuale del settore Life Sciences 10.6%.

Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 12.1% ) di QGEN è considerato basso.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/22 14:12
Prezzo dell'azione a fine giornata2026/07/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Qiagen N.V. è coperta da 40 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Charles ButlerBarclays